Oral nano?curcumin formulation efficacy in management of mild to moderate hospitalized <scp>coronavirus disease</scp> ?19 patients: An open label nonrandomized clinical trial

Curcumin is proposed as a potential treatment option for coronavirus disease-19 (COVID-19) by inhibiting the virus entrance, encapsulation and replication, modulating various cellular signaling pathways. In this open-label nonrandomized clinical trial, efficacy of nano-curcumin oral formulation has been evaluated in hospitalized patients with mild–moderate COVID-19. Forty-one who fulfilled inclusion criteria were allocated to (n = 21) group (Sinacurcumin soft gel, contains 40 mg curcuminoids nanomicelles, two capsules twice day) or control 20) group, 2 weeks. Patients' symptoms laboratory data assessed at baseline during follow-up period. Most including fever chills, tachypnea, myalgia, cough resolved significantly faster curcumin group. Moreover, SaO2 was higher after 2, 4, 7, 14 days lymphocyte count 7 days. Duration supplemental O2 use hospitalization also meaningfully shorter It noteworthy mention that no patient experienced deterioration infection period, but it occurred 40% Oral nano-formulation can improve recovery time COVID-19 patients. Further randomized placebo controlled trials larger sample size are recommended.